de Boni, Laura https://orcid.org/0000-0001-7785-482X
Wallis, Amber
Hays Watson, Aurelia
Ruiz-Riquelme, Alejandro https://orcid.org/0000-0001-6581-7132
Leyland, Louise-Ann
Bourinaris, Thomas
Hannaway, Naomi
Wüllner, Ullrich
Peters, Oliver
Priller, Josef https://orcid.org/0000-0001-7596-0979
Falkenburger, Björn H
Wiltfang, Jens https://orcid.org/0000-0003-1492-5330
Bähr, Mathias
Zerr, Inga
Bürger, Katharina
Perneczky, Robert https://orcid.org/0000-0003-1981-7435
Teipel, Stefan
Löhle, Matthias
Hermann, Wiebke
Schott, Björn-Hendrik https://orcid.org/0000-0002-8237-4481
Brockmann, Kathrin
Spottke, Annika
Haustein, Katrin
Breuer, Peter
Houlden, Henry
Weil, Rimona S https://orcid.org/0000-0002-5092-6325
Bartels, Tim https://orcid.org/0000-0002-4071-5612
Funding for this research was provided by:
Deutsches Zentrum für Neurodegenerative Erkrankungen (n.a.)
Deutsches Zentrum für Neurodegenerative Erkrankungen (n.a.)
University Bonn (n.a.)
Maria Zambrano Fellowship (n.a.)
Ministerio de Ciencia e Innovación (PID2021-1265840A-100)
ERDF (n.a.)
Rosetrees Trust (n.a.)
Deutsche Forschungsgemeinschaft (n.a.)
Bundesministerium für Bildung und Forschung (n.a.)
University of Bonn (n.a.)
Wellcome Trust (205167)
NIH UK (n.a.)
NIH UK (n.a.)
DRI (n.a.)
Eisei pharmaceuticals (n.a.)
US National Institute of Neurological Disorders (nU54,2xR01)
Chan Zuckerberg Collaborative Pairs Initiative Phase 2 (n.a.)
UK Dementia Research Institute (DRI), which receives its funding from DRI Ltd., the UK Medical Research Council and Alzheimer’s Society, and Alzheimer’s Research UK.
Article History
Received: 5 February 2024
Revised: 2 May 2024
Accepted: 17 May 2024
First Online: 5 June 2024
Disclosure and competing interests statement
: UW received consulting fees/contracting fees from STADA Pharm, Idorsia, Zambon, Abbvie, Bayer, Bial, and Roche. RSW has received speaking honoraria from GE Healthcare and writing honoraria from Britannia. RSW has received fees for consulting for Therakind. TB received consulting/contracting fees from Jennsen and Arvinas, part of the research was conducted by research funds provided Eisai Pharmaceuticals.